Voyager Therapeutics, Inc. (VYGR) Financials

VYGR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 219.3 million 45.7 million
Dec. 31, 2025 252.3 million 56.2 million
Sept. 30, 2025 288.3 million 68.5 million
June 30, 2025 322.1 million 78.2 million

VYGR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -33.4 million 2.5 million
Dec. 31, 2025 -30.9 million 3.5 million
Sept. 30, 2025 -31.3 million 3.5 million
June 30, 2025 -34.4 million 4.1 million

VYGR Net Income

No data available :(

VYGR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 141.5 million - 34.6 million
Dec. 31, 2025 196.4 million - 28.7 million
Sept. 30, 2025 208.9 million - 38.4 million
June 30, 2025 215.6 million - 40.2 million

VYGR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 59.5 million
Dec. 31, 2025 58.7 million
Sept. 30, 2025 58.8 million
June 30, 2025 58.7 million

VYGR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 14000 24.6 million 8.3 million -
Dec. 31, 2025 626000 36.0 million 9.3 million -
Sept. 30, 2025 207000 35.9 million 8.1 million -
June 30, 2025 1.1 million 31.3 million 10.5 million -

VYGR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 2.6 million 932000
Dec. 31, 2025 15.3 million 1.0 million
Sept. 30, 2025 13.4 million -
June 30, 2025 5.2 million -

VYGR

Price: $3.10

52 week price:
2.88
5.55

Earnings Per Share: -1.98 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 275000

Ebitda: -22.9 million

Market Capitalization: 218.7 million

Links: